tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Novo Nordisk A/S

NVO
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
46.600USD
-0.910-1.92%
์ข…๊ฐ€ย 09-04 16:00๏ผˆET๏ผ‰
156.20B์‹œ๊ฐ€์ด์•ก
10.91P/E TTM

NVO ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Novo Nordisk A/S์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋А ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Novo Nordisk A/S ์‹ค์  ๋ฐœํ‘œ์ผ

์ตœ์‹  ์ถœ์‹œ
Aug 4, 2026
EPS / ์˜ˆ์ƒ
0.74/0.77
์ˆ˜์ต / ์˜ˆ์ƒ
12.21B/11.11B
์ฃผ๊ธฐ
FY2025 ์žฌ๋ฌด์ œํ‘œ
์ˆ˜์ต(YoY)
46.70B
10.88%
EPS(YoY)
3.48
5.93%
์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€
HOLD
2026/09/06
๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
YOY
๋นˆ ํ–‰ ์ˆจ๊ธฐ๊ธฐ
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
์žฌ๋ฌด ์ง€ํ‘œ
EPS
-18.78%0.74
85.74%1.71
4.03%0.94
-21.92%0.71
39.57%0.91
11.02%0.92
26.73%0.91
23.23%0.90
2.66%0.65
30.83%0.83
74.89%0.72
--0.73
--0.63
--0.63
--0.41
--1.32
----
----
----
----
์ˆ˜์ต
4.55%12.21B
37.80%15.17B
0.69%12.34B
11.81%11.74B
18.85%11.67B
15.63%11.01B
28.92%12.25B
22.51%10.50B
23.78%9.82B
23.77%9.52B
44.11%9.50B
38.88%8.57B
34.20%7.94B
21.33%7.69B
11.89%6.60B
9.31%6.17B
10.52%5.91B
15.66%6.34B
14.50%5.89B
16.39%5.65B
์ˆœ์ด์ต
-18.92%3.26B
85.87%7.61B
3.84%4.19B
-22.07%3.13B
39.12%4.03B
10.58%4.09B
27.38%4.04B
22.55%4.02B
1.91%2.89B
29.61%3.70B
70.04%3.17B
68.13%3.28B
48.77%2.84B
33.25%2.86B
11.29%1.86B
1.57%1.95B
-2.78%1.91B
4.71%2.14B
12.21%1.67B
18.91%1.92B
์ˆœ์ด์ต๋ฅ 
-22.45%26.74%
34.88%50.15%
3.13%33.98%
-30.30%26.68%
17.05%34.48%
-4.37%37.18%
-1.20%32.95%
0.03%38.28%
-17.66%29.46%
4.72%38.88%
17.99%33.35%
--38.27%
--35.78%
--37.13%
--28.26%
--32.54%
----
----
----
----
์ด ์ด์ต๋ฅ 
-6.09%78.21%
2.95%85.96%
-4.65%80.86%
-9.53%76.12%
-1.91%83.29%
-1.57%83.49%
0.00%84.80%
0.82%84.14%
-0.73%84.90%
0.19%84.83%
2.39%84.80%
--83.46%
--85.53%
--84.67%
--82.82%
--84.34%
----
----
----
----
๋ถ€์ฑ„๋น„์œจ
14.40%23.55%
7.85%26.18%
9.31%24.12%
37.83%19.76%
33.28%20.59%
169.42%24.27%
156.97%22.07%
62.11%14.33%
68.72%15.45%
-11.74%9.01%
-19.65%8.59%
--8.84%
--9.16%
--10.21%
--10.69%
--10.69%
----
----
----
----
์ˆ˜์ต
4.55%12.21B
37.80%15.17B
0.69%12.34B
11.81%11.74B
18.85%11.67B
15.63%11.01B
28.92%12.25B
22.51%10.50B
23.78%9.82B
23.77%9.52B
44.11%9.50B
38.88%8.57B
34.20%7.94B
21.33%7.69B
11.89%6.60B
9.31%6.17B
10.52%5.91B
15.66%6.34B
14.50%5.89B
16.39%5.65B
์˜์—… ์ด์ต
1.41%5.25B
70.80%9.34B
-3.92%5.05B
4.31%5.20B
13.40%5.18B
17.87%5.47B
36.02%5.25B
26.80%4.98B
30.77%4.57B
28.72%4.64B
64.83%3.86B
43.67%3.93B
32.47%3.49B
24.81%3.60B
11.77%2.34B
13.11%2.73B
10.12%2.64B
18.88%2.89B
17.08%2.10B
20.30%2.42B
์ˆœ์ด์ต
-18.92%3.26B
85.87%7.61B
3.84%4.19B
-22.07%3.13B
39.12%4.03B
10.58%4.09B
27.38%4.04B
22.55%4.02B
1.91%2.89B
29.61%3.70B
70.04%3.17B
68.13%3.28B
48.77%2.84B
33.25%2.86B
11.29%1.86B
1.57%1.95B
-2.78%1.91B
4.71%2.14B
12.21%1.67B
18.91%1.92B
์œ ๋™์ž์‚ฐ
24.05%31.89B
8.45%27.42B
21.40%27.12B
-1.93%28.59B
0.80%25.71B
50.08%25.29B
8.05%22.34B
44.58%29.15B
26.48%25.50B
1.59%16.85B
32.75%20.68B
27.99%20.16B
38.88%20.16B
28.81%16.58B
19.01%15.57B
10.94%15.75B
18.02%14.52B
32.95%12.88B
21.15%13.09B
22.44%14.20B
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
11.43%36.54B
1.72%34.82B
12.29%33.92B
18.36%36.84B
21.45%32.79B
42.85%34.24B
20.24%30.20B
27.20%31.13B
17.60%27.00B
24.78%23.97B
44.28%25.12B
42.46%24.47B
48.50%22.96B
35.03%19.21B
14.42%17.41B
24.89%17.18B
33.18%15.46B
24.57%14.22B
31.91%15.22B
23.11%13.75B
์ด ์ž์‚ฐ
19.34%90.92B
21.94%86.49B
32.02%85.38B
35.64%80.53B
43.54%76.18B
63.95%70.92B
38.90%64.67B
39.51%59.37B
28.96%53.07B
18.87%43.26B
34.07%46.56B
32.90%42.56B
33.33%41.15B
24.07%36.39B
16.78%34.73B
18.13%32.02B
22.44%30.87B
31.51%29.33B
25.02%29.74B
23.01%27.10B
๋ถ€์ฑ„ ์ด๊ณ„
15.06%57.10B
8.35%55.08B
22.59%54.86B
30.11%53.82B
34.47%49.63B
75.64%50.84B
45.37%44.75B
40.85%41.37B
32.31%36.91B
16.88%28.95B
35.55%30.78B
34.05%29.37B
36.94%27.89B
27.47%24.77B
20.03%22.71B
30.33%21.91B
38.04%20.37B
48.59%19.43B
41.28%18.92B
32.84%16.81B
์ž๋ณธ ์ด๊ณ„
27.34%33.81B
56.35%31.41B
53.18%30.52B
48.34%26.71B
64.25%26.56B
40.33%20.09B
26.28%19.92B
36.53%18.00B
21.90%16.17B
23.13%14.31B
31.28%15.78B
30.42%13.19B
26.35%13.26B
17.41%11.63B
11.11%12.02B
-1.77%10.11B
0.41%10.50B
7.30%9.90B
4.06%10.82B
9.74%10.29B
์ˆœ์˜์—…์ด์ต
36.97%8.31B
5.78%3.67B
-32.48%1.19B
11.81%7.22B
-15.00%6.19B
66.24%3.47B
27.63%1.76B
8.00%6.46B
74.52%7.29B
-51.47%2.09B
41.53%1.38B
82.10%5.98B
21.63%4.18B
20.79%4.30B
309.90%973.84M
-3.69%3.28B
-16.04%3.43B
94.93%3.56B
-1783.79%-463.95M
24.14%3.41B
์ˆœํˆฌ์ž
2.04%-2.00B
-99.43%-1.88B
48.84%-6.67B
21.53%-2.42B
27.67%-2.16B
-263.22%-940.65M
-514.22%-13.05B
-59.27%-3.08B
-120.49%-2.99B
160.16%576.30M
-11.81%-2.12B
-187.62%-1.93B
-125.46%-1.36B
-233.08%-958.00M
40.05%-1.90B
8.54%-672.14M
-28.79%-601.82M
49.04%-287.62M
-53.31%-3.17B
22.75%-734.88M
์ˆœ์žฌ๋ฌดํ™œ๋™
61.66%-2.69B
-436.25%-2.58B
-12.79%4.59B
1.20%-2.68B
-391.65%-7.02B
119.99%768.39M
460.85%5.27B
6.38%-2.71B
230.87%2.41B
-29.32%-3.84B
-38.82%-1.46B
-46.73%-2.90B
-23.08%-1.84B
-2.98%-2.97B
-250.33%-1.05B
-6.08%-1.97B
-140.64%-1.49B
-22.97%-2.89B
1312.98%699.54M
-10.85%-1.86B

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Novo Nordisk A/S์˜ ์ด์ˆ˜์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋งค์ถœ์€ 46.70B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 42.12B์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 27.12B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 21.40์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ด์ž์‚ฐ์€ 85.38B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 32.02์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ด๋ถ€์ฑ„๋Š” 54.86B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 22.59์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ด์ž๋ณธ์€ 30.52B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 53.18์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ˆœ์˜์—…์†Œ๋“์€ 21.61B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 7.25์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ˆœํˆฌ์ž๋Š” -11.96B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 36.02์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novo Nordisk A/S์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ -4.29B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -438.82์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ 3.48์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 5.93์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ 15.48B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 5.67์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ˆœ์ด์ต๋ฅ ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต๋ฅ ์€ 33.14์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -4.69์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ๋งค์ถœ์ด์ด์ต๋ฅ ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋งค์ถœ์ด์ด์ต๋ฅ ์€ 82.51์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -2.83์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ๋ถ€์ฑ„/์ž์‚ฐ ๋น„์œจ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋ถ€์ฑ„/์ž์‚ฐ ๋น„์œจ์€ 24.12์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 9.31์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ 61.38์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -25.21์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ 20.63์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -21.66์ž…๋‹ˆ๋‹ค.

Novo Nordisk A/S์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novo Nordisk A/S์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ 21.61B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 7.25์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ